National News
Expedited Access to Biosimilars Act Introduced
Content Files PDF XML TEXT Metadata download Descriptive Metadata (MODS) Preservation Metadata (PREMIS) All Content and Metadata files, including granules ZIP
Last updated:
Key points
- H.R. 9661 aims to improve access to biosimilars in the U.S.
- The legislation seeks to streamline approval processes for these medications.
- The move is designed to enhance competition and lower drug costs.
Impact of H.R. 9661 and New Biosimilar Legislation
NewsWK — A new piece of legislation, known as H.R. 9661, has been introduced to enhance the accessibility of biosimilars in the United States. The Expedited Access to Biosimilars Act aims to streamline the approval process for these biologic medications, which are increasingly seen as cost-effective alternatives to traditional biologics.
Streamlining the Biosimilar Approval Process
The bill seeks to address current regulatory hurdles that may delay the entry of biosimilars into the market, potentially benefiting patients and healthcare providers alike by increasing competition and reducing drug costs.
For more details on the legislation, including full text and metadata, visit the official government document repository at GovInfo.
Based on reporting originally published by GovInfo (U.S. GPO). Read the original story.
Related: Congress Receives New Legislation Aimed at Local Health Care Protection
Related: Sanctuary Policies Block Federal Jail Transfers as ICE Ramps Up Enforcement Across U.S. Communities
See a typo? Report it here.
